The dopamine transporter (DAT) has been identified as a principal brain receptor site previously correlated with the rewarding and euphoric properties of cocaine. Euphoric responses to rapid administration of cocaine can be much more prominent than those that follow slower rates of administration. In previous years, investigators in this Branch have found that activators of protein kinase C (PKC) modulate dopamine transport in transiently-expressing COS cells and identified DAT as a phosphoprotein effected by several PKC, MAP kinase, MEKkinase and IP3 kinase agents. These studies have documented that the DAT regulation can occur as internalization of the transporter or as downregulation of the function of the transporter that remains expressed on cell surfaces, using activation of distince kinase pthways. Work during this year has also provided insights into functions of the human allelic variants in the DAT 5' flanking region. Human variants and haplotypes from this region have beeen identified by genomic resequencing. Large constructions containing a number of variants in each of the two most prominent haplotypes have been expressed in two cell expression systems as luciferase fusion constructions. Interestingly, these results provide evidence for a 30-50% haplotype-dependent difference in levels of DAT expression. In vivo PET and postmortem studies appear to confirm these observations in vivo. This work appears to complement studies of regulation at a protein phospphorylation level to provide a more complete picture of the state- and trait-dependent features of regulation of this important determinant of dopaminergic functions including those important for drug reward.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000159-10
Application #
7149275
Study Section
(MNRB)
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
2005
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Lin, Zhicheng; Uhl, George R (2005) Proline mutations induce negative-dosage effects on uptake velocity of the dopamine transporter. J Neurochem 94:276-87
Dohi, Toshihiro; Kitayama, Shigeo; Morioka, Norimitsu et al. (2004) Regulation of dopamine and MPP+ transport by catecholamine transporters. Nihon Shinkei Seishin Yakurigaku Zasshi 24:43-7
Lin, Zhicheng; Uhl, George R (2003) Human dopamine transporter gene variation: effects of protein coding variants V55A and V382A on expression and uptake activities. Pharmacogenomics J 3:159-68
Lin, Zhicheng; Zhang, Ping-Wu; Zhu, Xuguang et al. (2003) Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites. J Biol Chem 278:20162-70
Moron, Jose A; Zakharova, Irina; Ferrer, Jasmine V et al. (2003) Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 23:8480-8
Uhl, George R (2003) Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov Disord 18 Suppl 7:S71-80
Uhl, George R; Lin, Zhicheng (2003) The top 20 dopamine transporter mutants: structure-function relationships and cocaine actions. Eur J Pharmacol 479:71-82
Liu, Qing-Rong; Zhang, Ping-Wu; Zhen, Qiaoxi et al. (2002) KEPI, a PKC-dependent protein phosphatase 1 inhibitor regulated by morphine. J Biol Chem 277:13312-20